FGFR1 and neoplasm: Having taken a novel and unbiased approach to classification, our findings suggest that BRAF and FGFR1 mutations are highly specific within glioneuronal tumours to each of the two molecular tumour groups we have identified, and may be well suited as markers for distinguishing them from one another.